Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo shows promise for kids with resistant cancers

NCT ID NCT01282697

Completed Disease control Sponsor: University Hospital, Strasbourg, France Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 25 times

Summary

This early-phase study tested a combination of two drugs, rapamycin and irinotecan, in 42 children and young adults (ages 1-21) with solid tumors that did not respond to standard treatments. The main goal was to find the safest dose and understand side effects. The approach aims to stop tumor growth by blocking blood vessel development, but it is not a cure—ongoing treatment may be needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY SOLID TUMORS IN CHILDREN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CHU La Timone

    Marseille, 13005, France

  • CHU Mère-Enfants

    Nantes, 44093, France

  • Centre Oscar Lambret

    Lille, 59020, France

  • Hôpital des Enfants

    Toulouse, 31059, France

  • Hôpital des Enfants - Groupe Hospitalier Pellegrin

    Bordeaux, 33076, France

  • Hôpitaux Universitaires de Strasbourg

    Strasbourg, 67098, France

  • Institut Curie

    Paris, 75005, France

  • Institut Gustave Roussy

    Villejuif, 94805, France

  • Institut Hémato-Oncologie Pédiatrique (IHOP)

    Lyon, 67008, France

Conditions

Explore the condition pages connected to this study.

REFRACTORY SOLID TUMORS IN CHILDREN